Rogers Ashley E J, Eisenman Kristen M, Dolan Susan A, Belderson Kristin M, Zauche Jocelyn R, Tong Suhong, Gralla Jane, Hilden Joanne M, Wang Michael, Maloney Kelly W, Dominguez Samuel R
Department of Pediatric Oncology, University of Colorado Denver School of Medicine and Children's Hospital Colorado, Aurora, Colorado.
Department of Epidemiology, University of Colorado Denver School of Medicine and Children's Hospital Colorado, Aurora, Colorado.
Pediatr Blood Cancer. 2017 Mar;64(3). doi: 10.1002/pbc.26254. Epub 2016 Sep 12.
Central line-associated blood stream infections (CLABSIs) are a source of high morbidity and mortality in children with acute myelogenous leukemia (AML).
To understand the epidemiology and risk factors associated with the development of CLABSI in children with AML.
We retrospectively reviewed all patients with AML over a 5-year period between 2007 and 2011 at the Children's Hospital Colorado. Cases and controls were classified on the basis of the presence of a CLABSI as defined by the National Healthcare Safety Network.
Of 40 patients in the study, 25 (62.5%) developed at least one CLABSI during therapy. The majority of CLABSIs were due to oral or gastrointestinal organisms (83.0%). Skin organisms accounted for 8.5%. In a multivariable analysis, the strongest risk factors associated with CLABSI were diarrhea (odds ratio [OR] 6.7, 95% confidence interval [CI] 1.6-28.7), receipt of blood products in the preceding 4-7 days (OR 10.0, 95%CI 3.2-31.0), not receiving antibiotics (OR 8.3, 95%CI 2.8-25.0), and chemotherapy cycle (OR 3.5, 95%CI 1.4-8.9). CLABSIs led to increased morbidity, with 13 cases (32.5%) versus two controls (1.9%) requiring transfer to the pediatric intensive care unit (P < 0.001). Three (7.5%) of 40 CLABSI events resulted in or contributed to death.
Intensified line care efforts cannot eliminate all CLABSIs in the patients with AML. Exploring the role of mucosal barrier breakdown and/or the use of antibiotic prophylaxis may be effective strategies for further prevention of CLABSIs, supporting ongoing trials in this patient population.
中心静脉导管相关血流感染(CLABSI)是急性髓性白血病(AML)患儿发病和死亡的一个原因。
了解与AML患儿发生CLABSI相关的流行病学及危险因素。
我们回顾性分析了2007年至2011年期间科罗拉多儿童医院5年内所有AML患者。病例和对照根据国家医疗安全网络定义的CLABSI情况进行分类。
在该研究的40例患者中,25例(62.5%)在治疗期间发生了至少一次CLABSI。大多数CLABSI是由口腔或胃肠道微生物引起的(83.0%)。皮肤微生物占8.5%。在多变量分析中,与CLABSI相关的最强危险因素是腹泻(比值比[OR]6.7,95%置信区间[CI]1.6 - 28.7)、在之前4 - 7天接受血液制品(OR 10.0,95%CI 3.2 - 31.0)、未接受抗生素治疗(OR 8.3,95%CI 2.8 - 25.0)以及化疗周期(OR 3.5,95%CI 1.4 - 8.9)。CLABSI导致发病率增加,13例(32.5%)病例与2例对照(1.9%)需要转入儿科重症监护病房(P < 0.001)。40例CLABSI事件中有3例(7.5%)导致死亡或促使死亡。
加强导管护理措施无法消除AML患者中的所有CLABSI。探索黏膜屏障破坏的作用和/或使用抗生素预防可能是进一步预防CLABSI的有效策略,这支持了针对该患者群体正在进行的试验。